These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 25967932)

  • 1. Brentuximab vedotin for the treatment of Hodgkin's lymphoma.
    Pham A; Chen R
    Expert Rev Hematol; 2015 Aug; 8(4):403-12. PubMed ID: 25967932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin for the treatment of CD30+ lymphomas.
    Foyil KV; Bartlett NL
    Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy.
    Illés Á; Jóna Á; Miltényi Z
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):451-9. PubMed ID: 25642958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
    Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
    Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
    Gualberto A
    Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
    Haddley K
    Drugs Today (Barc); 2012 Apr; 48(4):259-70. PubMed ID: 22536568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of antibody-drug conjugate brentuximab vedotin in treating Hodgkin's lymphoma.
    Viviani S; Guidetti A
    Expert Opin Biol Ther; 2018 Aug; 18(8):841-849. PubMed ID: 29999431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
    Chen R; Chen B
    Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.
    Ansell SM
    Expert Opin Investig Drugs; 2011 Jan; 20(1):99-105. PubMed ID: 21121873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
    Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
    Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.
    Younes A
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):27-32. PubMed ID: 24287065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
    Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
    Bradley AM; Devine M; DeRemer D
    Am J Health Syst Pharm; 2013 Apr; 70(7):589-97. PubMed ID: 23515511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
    Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin.
    Deng C; Pan B; O'Connor OA
    Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
    Oak E; Bartlett NL
    Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin in systemic T-cell lymphoma.
    Oki Y; Younes A
    Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.